Dr. Lal Path Labs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Dr. Lal Path Labs Q2 results FY27 announcement is the next scheduled earnings event for Dr. Lal PathLabs Ltd., Dr. Lal PathLabs runs a nationwide network of diagnostic and pathology laboratories and sample collection centres, offering blood tests, imaging, and health checkup packages to patients, doctors and hospitals across India.. The stock traded at Rs 1,907.40 on the NSE on 17 September 2026, up 0.62% from the previous close of Rs 1,895.70, about 6.4% below its 52-week high of Rs 2,038.60 and 49.9% above its 52-week low of Rs 1,272.60.

What makes the Dr. Lal Path Labs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 731.00 crore of revenue and a profit of Rs 152.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 798.00 crore and a profit of Rs 170.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Dr. Lal Path Labs Q2 Results FY27 Date?

The Dr. Lal Path Labs Q2 results date for FY27 is not confirmed. As of 17 September 2026, Dr. Lal PathLabs Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

Also read – CAMS: Steady Growth Trend Into Q2 Results

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Dr. Lal Path Labs Q2 results date becomes public through that filing rather than through any advance announcement.

The Dr. Lal Path Labs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Dr. Lal Path Labs.

Dr. Lal Path Labs Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Dr. Lal Path Labs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Dr. Lal Path Labs. The Dr. Lal Path Labs Q2 results watchlist below is built from what the company has actually reported and disclosed.

Dr. Lal Path Labs Q2 results for the September 2026 quarter will be measured against a base that has already shown how uneven this business can be from one quarter to the next. Revenue moved from Rs 670 crore in the June 2025 quarter to Rs 731 crore in the September 2025 quarter, then slipped to Rs 660 crore in the December 2025 quarter before climbing back to Rs 703 crore in the March 2026 quarter and Rs 798 crore in the June 2026 quarter. Net profit told a similar story, falling from Rs 152 crore in the September 2025 quarter to Rs 91 crore in the December 2025 quarter, then recovering to Rs 132 crore and Rs 170 crore in the following two quarters, so anyone framing expectations for Dr. Lal Path Labs Q2 results should factor in that kind of sequential swing rather than assume a straight line.

On profitability, the operating margin has ranged between 27% and 31% over the last five quarters, and the company's return on equity of 22.3% and return on capital employed of 28% point to a business that continues to earn well above its cost of capital even after the softer December 2025 quarter. The diagnostics sector as a whole has been dealing with pricing pressure from price caps in some states and rising competition from organised chains and online booking platforms, which keeps volume growth and test mix as important swing factors for margins alongside reagent and staffing costs. A price to earnings multiple above 56 means the stock is priced for continued earnings growth, so these are the trends that will frame how the market reads Dr. Lal Path Labs Q2 results once they are out, and how it treats Dr. Lal Path Labs Q2 results in the days after they land.

Also read – CDSL Q2 Results Preview: What the Numbers Show

Putting it together, Dr. Lal Path Labs Q2 results for the September 2026 quarter arrive with revenue that has grown over the last year but with profit that has been choppy quarter to quarter, so the pattern of past swings is worth keeping in mind rather than expecting a smooth repeat of the June 2026 quarter's rebound. Whatever the actual print for the September 2026 quarter turns out to be, comparing it against the June 2025, September 2025, December 2025, March 2026 and June 2026 quarters already on record is the most grounded way to judge Dr. Lal Path Labs Q2 results and whether the recovery in profit has held.

Check Dr. Lal PathLabs Ltd. Live Fundamentals on the Univest Screener

Dr. Lal Path Labs Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Dr. Lal PathLabs Ltd. reported revenue of Rs 798.00 crore in Q1 FY27, up 19.10% from Rs 670.00 crore in Q1 FY26, and a profit of Rs 170.00 crore at the net level, up 26.87% from Rs 134.00 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 13.51% over the March 2026 quarter figure of Rs 703.00 crore, and net profit was up 28.79% from Rs 132.00 crore in Q4 FY26. Operating margin stood at 29.0% in Q1 FY27 against 31.0% in the September 2025 quarter, which is the comparison the Dr. Lal Path Labs Q2 results print will be read against.

Q2 FY26 Base: The Comparison Dr. Lal Path Labs Q2 Results FY27 Must Beat

Dr. Lal PathLabs Ltd. reported revenue of Rs 731.00 crore and a profit of Rs 152.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Dr. Lal Path Labs Q2 results preview.

Net profit in that base quarter was below the Rs 170.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 731.00 crore sits below the Rs 798.00 crore of the June 2026 quarter, which frames how much sequential movement the Dr. Lal Path Labs Q2 results print needs to show growth.

Dr. Lal Path Labs Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	731.00	152.00
Q3 FY26 (Dec 2025)	660.00	91.00
Q4 FY26 (Mar 2026)	703.00	132.00
Q1 FY27 (Jun 2026)	798.00	170.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Dr. Lal Path Labs Q2 results preview uses.

Revenue across those four quarters ranged from Rs 660.00 crore to Rs 798.00 crore, and net profit from Rs 91.00 crore to Rs 170.00 crore. That spread is the honest context for the Dr. Lal Path Labs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Dr. Lal Path Labs Q2 Results FY27

The Dr. Lal Path Labs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Dr. Lal Path Labs has already reported.

Revenue and profit trend

Over the five quarters from June 2025 to June 2026, Dr. Lal Path Labs has posted revenue between Rs 660 crore and Rs 798 crore, growing overall but not every quarter in a straight line. Net profit ranged from Rs 91 crore to Rs 170 crore across the same period, with the December 2025 quarter marking the low point and the June 2026 quarter the high point. This is the base against which Dr. Lal Path Labs Q2 results for the September 2026 quarter will be compared, and it is the reason Dr. Lal Path Labs Q2 results are being watched closely this cycle.

Margins and returns

The operating margin has stayed in a relatively narrow 27% to 31% band across the last five quarters, and return on equity of 22.3% alongside return on capital employed of 28% remain healthy by broader market standards. A debt to equity ratio of just 0.08 shows the balance sheet carries very little borrowed money, so most of the swing in profit comes from operating performance rather than interest costs. A steady balance sheet like this is generally seen as supportive going into Dr. Lal Path Labs Q2 results, since it reduces financing risk regardless of how revenue trends this cycle.

Valuation to watch

At a price to earnings multiple above 56 and a price to book ratio near 12.7, the stock trades at a premium that assumes both margin stability and continued growth. The direction of Dr. Lal Path Labs Q2 results, particularly on margin and profit rather than revenue alone, is likely to matter more to the market than the headline sales number attached to Dr. Lal Path Labs Q2 results this time.

Dr. Lal Path Labs Q2 Results FY27: Share Price and Valuation Going Into the Print

Dr. Lal Path Labs share price today is Rs 1,907.40 on the NSE, up Rs 11.70 or 0.62% from the previous close of Rs 1,895.70 on 17 September 2026, ahead of the Dr. Lal Path Labs Q2 results announcement.

Metric	Value (17 September 2026)
NSE Symbol	LALPATHLAB
Current Market Price	Rs 1,907.40
52-Week High	Rs 2,038.60
52-Week Low	Rs 1,272.60
Market Capitalisation	Rs 32007 crore
PE Ratio	56.88
PB Ratio	12.72
EPS (TTM)	Rs 33.53
Book Value per Share	Rs 150.00
Debt to Equity	0.08
Return on Equity	22.30%
50-Day Moving Average	Rs 1859.77
200-Day Moving Average	Rs 1571.51
RSI (14)	43.19

The stock trades above both its 50-day average of Rs 1859.77 and its 200-day average of Rs 1571.51, with a 14-day RSI of 43.19. None of this is a view on where the shares go once the Dr. Lal Path Labs Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Dr. Lal PathLabs Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Dr. Lal Path Labs Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Dr. Lal Path Labs Q2 results print in proportion.

1. Revenue against the Rs 731.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 152.00 crore in that same quarter
3. Operating margin against 29.0% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Dr. Lal Path Labs Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Dr. Lal Path Labs Q2 Results FY27

The Dr. Lal Path Labs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Dr. Lal PathLabs Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Dr. Lal Path Labs Q2 results FY27 print faces a base of Rs 731.00 crore in revenue and a profit of Rs 152.00 crore, with the most recent quarter having delivered Rs 798.00 crore and a profit of Rs 170.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Dr. Lal Path Labs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Dr. Lal Path Labs Q2 Results FY27

What is the Dr. Lal Path Labs Q2 results date for FY27?

Ans. The Dr. Lal Path Labs Q2 results date for FY27 is not confirmed. Dr. Lal PathLabs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Dr. Lal Path Labs Q2 results 2026 cover?

Ans. The Dr. Lal Path Labs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Dr. Lal PathLabs Ltd. reports revenue, operating profit and net profit for that period, and the Dr. Lal Path Labs Q2 results filing also carries the notes to the accounts.

What were the Dr. Lal Path Labs Q1 FY27 results?

Ans. Dr. Lal PathLabs Ltd. reported revenue of Rs 798.00 crore in Q1 FY27 and a profit of Rs 170.00 crore at the net level. Revenue was up 19.10% versus Q1 FY26 and net profit was up 26.87% from Rs 134.00 crore in Q1 FY26.

What were Dr. Lal Path Labs Q2 FY26 results in the September 2025 quarter?

Ans. Dr. Lal PathLabs Ltd. reported revenue of Rs 731.00 crore and a profit of Rs 152.00 crore in Q2 FY26. Operating margin was 31.0%. Those figures form the base for the Dr. Lal Path Labs Q2 results FY27 comparison.

What are the main Dr. Lal Path Labs Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Dr. Lal Path Labs Q2 results expectations centre on revenue against the Rs 731.00 crore base, net profit against a profit of Rs 152.00 crore, operating margin against 29.0% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Dr. Lal Path Labs share price today ahead of the Q2 earnings?

Ans. Dr. Lal Path Labs share price is Rs 1,907.40 on the NSE as of 17 September 2026, up 0.62% from Rs 1,895.70. The stock is about 6.4% below its 52-week high of Rs 2,038.60 and 49.9% above its 52-week low of Rs 1,272.60, at a market capitalisation of Rs 32007 crore.

Is Dr. Lal Path Labs a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Dr. Lal PathLabs Ltd. The stock trades at a price-to-book ratio of 12.72 with a return on equity of 22.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.